JP2020506225A - 心血管疾患を処置するための方法およびキット - Google Patents

心血管疾患を処置するための方法およびキット Download PDF

Info

Publication number
JP2020506225A
JP2020506225A JP2019559166A JP2019559166A JP2020506225A JP 2020506225 A JP2020506225 A JP 2020506225A JP 2019559166 A JP2019559166 A JP 2019559166A JP 2019559166 A JP2019559166 A JP 2019559166A JP 2020506225 A JP2020506225 A JP 2020506225A
Authority
JP
Japan
Prior art keywords
subject
human subject
il1b
drug
pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019559166A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020506225A5 (https=
Inventor
ケネス コーンマン
ケネス コーンマン
リン ドウセット−スタム
リン ドウセット−スタム
ゴードン ダフ
ゴードン ダフ
Original Assignee
カーディオフォーキャスト リミテッド
カーディオフォーキャスト リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カーディオフォーキャスト リミテッド, カーディオフォーキャスト リミテッド filed Critical カーディオフォーキャスト リミテッド
Publication of JP2020506225A publication Critical patent/JP2020506225A/ja
Publication of JP2020506225A5 publication Critical patent/JP2020506225A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019559166A 2017-01-12 2018-01-12 心血管疾患を処置するための方法およびキット Pending JP2020506225A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762445395P 2017-01-12 2017-01-12
US62/445,395 2017-01-12
US15/649,175 2017-07-13
US15/649,177 2017-07-13
US15/649,177 US10329620B2 (en) 2017-01-12 2017-07-13 Methods and kits for treating cardiovascular disease
US15/649,175 US10337070B2 (en) 2017-01-12 2017-07-13 Methods and kits for treating cardiovascular disease
PCT/EP2018/050795 WO2018130670A1 (en) 2017-01-12 2018-01-12 Methods and kits for treating cardiovascular disease

Publications (2)

Publication Number Publication Date
JP2020506225A true JP2020506225A (ja) 2020-02-27
JP2020506225A5 JP2020506225A5 (https=) 2021-02-12

Family

ID=62782270

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019559166A Pending JP2020506225A (ja) 2017-01-12 2018-01-12 心血管疾患を処置するための方法およびキット

Country Status (5)

Country Link
US (3) US10337070B2 (https=)
EP (1) EP3568495B1 (https=)
JP (1) JP2020506225A (https=)
CA (1) CA3050035A1 (https=)
WO (1) WO2018130670A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017123696A1 (en) 2016-01-12 2017-07-20 Interleukin Genetics, Inc. Methods for predicting response to treatment
US10337070B2 (en) 2017-01-12 2019-07-02 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease
US10357476B1 (en) * 2018-10-30 2019-07-23 Anis Ahmad Method for treating coronary artery disease
EP3969620B1 (en) * 2019-05-17 2025-06-25 Regeneron Pharmaceuticals, Inc. Genome-based methods for reducing cardiovascular risk
WO2021028469A1 (en) * 2019-08-12 2021-02-18 Sitokine Limited Compositions and methods for treating cytokine release syndrome and neurotoxicity
WO2021205013A1 (en) * 2020-04-09 2021-10-14 Sitokine Limited Compositions and methods for treating covid-19
CN116171161A (zh) 2020-08-25 2023-05-26 雷杰纳荣制药公司 用pcsk9和ldlr调节剂治疗败血症
CN112080563B (zh) * 2020-09-01 2021-04-30 美思睿(北京)生物科技有限公司 一种检测慢性病精准用药基因的试剂盒

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009515557A (ja) * 2005-11-17 2009-04-16 インターロイキン ジェネティクス， インコーポレイテッド 心血管疾患の診断および治療
JP2012504657A (ja) * 2008-10-03 2012-02-23 オーピーケーオー・クルナ・エルエルシー アポリポタンパク質−ａ１に対する天然アンチセンス転写物の抑制によるアポリポタンパク質−ａ１関連疾患の治療
WO2015142668A1 (en) * 2014-03-17 2015-09-24 Sanofi Methods for reducing cardiovascular risk
JP2019503176A (ja) * 2016-01-12 2019-02-07 インターロイキン ジェネティクス， インコーポレイテッド 処置に対する応答を予測するための方法

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
NO870613L (no) 1986-03-05 1987-09-07 Molecular Diagnostics Inc Deteksjon av mikroorganismer i en prŸve inneholdende nukleinsyre.
US4988617A (en) 1988-03-25 1991-01-29 California Institute Of Technology Method of detecting a nucleotide change in nucleic acids
JP2897959B2 (ja) 1988-05-20 1999-05-31 エフ．ホフマン―ラ ロシュ アクチェンゲゼルシャフト 固定化された配列特異的プローブ
US4988167A (en) 1988-08-10 1991-01-29 Fergason James L Light blocking and vision restoration apparatus with glint control
US5118801A (en) 1988-09-30 1992-06-02 The Public Health Research Institute Nucleic acid process containing improved molecular switch
CA2020958C (en) 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
US5494810A (en) 1990-05-03 1996-02-27 Cornell Research Foundation, Inc. Thermostable ligase-mediated DNA amplifications system for the detection of genetic disease
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5270184A (en) 1991-11-19 1993-12-14 Becton, Dickinson And Company Nucleic acid target generation
ATE198358T1 (de) 1992-04-27 2001-01-15 Dartmouth College Detektion von gensequenzen in biologischen flüssigkeiten
DE69433811T2 (de) 1993-01-07 2005-06-23 Sequenom, Inc., San Diego Dns - sequenzierung durch massenspektronomie
US5422252A (en) 1993-06-04 1995-06-06 Becton, Dickinson And Company Simultaneous amplification of multiple targets
US6027923A (en) 1993-07-23 2000-02-22 Bio-Rad Laboratories, Inc. Linked linear amplification of nucleic acids
US5527675A (en) 1993-08-20 1996-06-18 Millipore Corporation Method for degradation and sequencing of polymers which sequentially eliminate terminal residues
US5498531A (en) 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
DE4331012A1 (de) 1993-09-13 1995-03-16 Bayer Ag Nukleinsäuren-bindende Oligomere mit N-Verzweigung für Therapie und Diagnostik
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5657255C1 (en) 1995-04-14 2002-06-11 Interleukin Genetics Inc Hierarchic biological modelling system and method
US5686246A (en) 1995-08-03 1997-11-11 Kornman; Kenneth S. Detecting genetic predisposition to periodontal disease
EP2332957B1 (en) 1996-02-09 2015-04-08 Cornell Research Foundation, Inc. Detection of nucleic and acid sequence differences using the ligase detection reaction with addressable arrays
US5698399A (en) 1996-04-05 1997-12-16 Duff; Gordon W. Detecting genetic predisposition for osteoporosis
US6108635A (en) 1996-05-22 2000-08-22 Interleukin Genetics, Inc. Integrated disease information system
EP2369007B1 (en) 1996-05-29 2015-07-29 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
US5866336A (en) 1996-07-16 1999-02-02 Oncor, Inc. Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
US6117635A (en) 1996-07-16 2000-09-12 Intergen Company Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
GB9618960D0 (en) 1996-09-11 1996-10-23 Medical Science Sys Inc Proteases
GB9621129D0 (en) 1996-10-10 1996-11-27 Duff Gordon W Detecting genetic predisposition to sight-threatening diabetic retinopathy
US6524795B1 (en) 1997-03-10 2003-02-25 Interleukin Genetics, Inc. Diagnostics for cardiovascular disorders
US6210877B1 (en) 1997-03-10 2001-04-03 Interleukin Genetics, Inc. Prediction of coronary artery disease
US6720141B1 (en) 1999-11-01 2004-04-13 Interleukin Genetics, Inc. Diagnostics and therapeutics for restenosis
GB9723553D0 (en) 1997-11-07 1998-01-07 Duff Gordon W Prediction of the risk of chronic obstructive airway disease
GB9711040D0 (en) 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease
US20050282198A1 (en) 1997-05-29 2005-12-22 Interleukin Genetics, Inc. Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype
US6437216B1 (en) 1997-11-13 2002-08-20 Interleukin Genetics Inc. Transgenic models of inflammatory disease
US6746839B1 (en) 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
US20050032077A1 (en) 1998-03-10 2005-02-10 Duff Gordon W. Detecting genetic predisposition to sight-threatening diabetic retinopathy
US6733967B1 (en) 1998-04-21 2004-05-11 Interleukin Genetics, Inc. Fetal testing for prediction of low birth weight
US6251598B1 (en) 1998-10-30 2001-06-26 Interleukin Genetics, Inc. Methods for diagnosing sepsis
IL144492A0 (en) 1999-02-10 2002-05-23 Interleukin Genetics Inc Therapeutics and diagnostics based on an il-1b mutation
US6506594B1 (en) 1999-03-19 2003-01-14 Cornell Res Foundation Inc Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
EP1194590A2 (en) 1999-06-30 2002-04-10 Interleukin Genetics, Inc. Diagnostics and therapeutics for diseases associated with an il-1 inflammatory haplotype
US20090023147A1 (en) 1999-08-30 2009-01-22 Kenneth Kornman Diagnostics and therapeutics for osteoporosis
US20100255475A1 (en) 1999-08-30 2010-10-07 Kornman Kenneth S Diagnostics and therapeutics for osteoporosis
MXPA02002251A (es) 1999-08-30 2003-08-20 Interleukin Genetics Inc Diagnosticos y terapeuticos para osteoporosis.
WO2002000933A2 (en) 2000-06-23 2002-01-03 Interleukin Genetics, Inc. Screening assays for identifying modulators of the inflammatory or immune responses
US20060183161A1 (en) 2000-07-17 2006-08-17 Martin Nicklin IL-ILI gene and polypeptide products
CA2434136A1 (en) 2001-01-08 2002-07-11 Interleukin Genetics, Inc. Mammalian tribbles signaling pathways and methods and reagents related thereto
EP1407005A4 (en) 2001-06-11 2006-05-31 Interleukin Genetics Inc INTEGRATIVE TESTING TECHNIQUES FOR CONTROLLING MOLECULAR ASSEMBLY EVENTS
CA2450809A1 (en) 2001-06-15 2002-12-27 Interleukin Genetics, Inc. Methods for detecting and treating the early onset of aging-related conditions
US20080311581A1 (en) 2001-11-19 2008-12-18 David Wyllie Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases
WO2003044176A2 (en) 2001-11-19 2003-05-30 Interleukin Genetics, Inc. Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases
US20070264645A1 (en) 2002-01-25 2007-11-15 Kenneth Kornman IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes
CA2534365A1 (en) 2003-08-08 2005-02-17 Interleukin Genetics, Inc. Diagnostic and therapeutics for osteoporosis
US20080118920A1 (en) 2004-05-03 2008-05-22 Duff Gordon W Diagnostics And Therapeutics For Diseases Associated With An Il-1 Inflammatory Haplotype
US20060252050A1 (en) 2005-05-06 2006-11-09 Ordovas Jose M Genetic marker for weight regulation
US8105775B2 (en) 2005-10-25 2012-01-31 Interleukin Genetics, Inc. IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes
EP2034855A2 (en) 2006-05-12 2009-03-18 Interleukin Genetics, Inc. Food compositions and methods of treating periodontal disease
EP2089538B1 (en) 2006-11-15 2013-08-21 Interleukin Genetics, Inc. The il-1 gene cluster and insulin resistance: associated polymorphisms, haplotypes and methods of using same
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
US20090170105A1 (en) 2007-11-08 2009-07-02 Interleukin Genetics, Inc. Diagnostics for Aging-Related Dermatologic Disorders
JP5762282B2 (ja) 2008-05-02 2015-08-12 インタールーキン ジェネティクス， インコーポレイテッド 変形性関節症に関連する状態に対する遺伝的素因の検出
EP2304052A2 (en) 2008-05-02 2011-04-06 Interleukin Genetics, Inc. Detecting genetic predisposition to osteoarthritis associated conditions
US20100136561A1 (en) 2008-05-16 2010-06-03 Interleukin Genetics, Inc. Genetic Markers for Weight Management and Methods of Use Thereof
JP5651585B2 (ja) 2008-05-16 2015-01-14 インターロイキン ジェネティクス， インコーポレイテッド 体重管理のための遺伝子マーカーとその使用方法
EP2315856A2 (en) 2008-07-18 2011-05-04 Interleukin Genetics, Inc. Methods and compositions for pharmacogenetic analysis of anti-inflammatory drugs in the treatment of rheumatoid arthritis and other inflammatory diseases
US20100112570A1 (en) 2008-10-22 2010-05-06 Interleukin Genetics, Inc. Genetic Markers for Weight Management and Methods of Use Thereof
US20110008906A1 (en) 2009-07-09 2011-01-13 Interleukin Genetics, Inc. Genetic Association of Polymorphisms in Perilipin (PLIN) Gene With Resistance to Weight Loss
RU2018122965A (ru) 2010-12-09 2019-03-06 Оридж3н, Инк. Улучшенный способ и набор для определения тяжести и прогрессирования периодонтального заболевания
WO2013049278A1 (en) * 2011-09-30 2013-04-04 Novartis Ag USE OF IL-1 ß BINDING ANTIBODIES
US20160002624A1 (en) 2012-05-17 2016-01-07 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions
DK2992098T3 (da) 2013-05-01 2019-06-17 Ionis Pharmaceuticals Inc Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression
US10337070B2 (en) 2017-01-12 2019-07-02 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009515557A (ja) * 2005-11-17 2009-04-16 インターロイキン ジェネティクス， インコーポレイテッド 心血管疾患の診断および治療
JP2012504657A (ja) * 2008-10-03 2012-02-23 オーピーケーオー・クルナ・エルエルシー アポリポタンパク質−ａ１に対する天然アンチセンス転写物の抑制によるアポリポタンパク質−ａ１関連疾患の治療
WO2015142668A1 (en) * 2014-03-17 2015-09-24 Sanofi Methods for reducing cardiovascular risk
JP2019503176A (ja) * 2016-01-12 2019-02-07 インターロイキン ジェネティクス， インコーポレイテッド 処置に対する応答を予測するための方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HUMAN GENETICS, vol. 123, JPN6021051210, 2008, pages 387 - 398, ISSN: 0004829199 *
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 63, JPN6021051213, 2014, pages 1724 - 1734, ISSN: 0004829197 *
SCHIZOPHRENIA RESEARCH, vol. 169, JPN6021051212, 2015, pages 1 - 9, ISSN: 0004829198 *

Also Published As

Publication number Publication date
CA3050035A1 (en) 2018-07-19
US10337070B2 (en) 2019-07-02
WO2018130670A1 (en) 2018-07-19
EP3568495A1 (en) 2019-11-20
US20180195122A1 (en) 2018-07-12
US20180195121A1 (en) 2018-07-12
US11486006B2 (en) 2022-11-01
US20190360048A1 (en) 2019-11-28
EP3568495B1 (en) 2023-07-05
US10329620B2 (en) 2019-06-25

Similar Documents

Publication Publication Date Title
JP2020506225A (ja) 心血管疾患を処置するための方法およびキット
US11976328B2 (en) Methods for predicting risk of interstitial pneumonia
US20210164052A1 (en) Methods for predicting response to treatment
CA3202510A1 (en) Tl1a therapy compositions and methods of treatment therewith
US20070037183A1 (en) Diagnostic and therapeutic target for macular degeneration
WO2021205013A1 (en) Compositions and methods for treating covid-19
US20140087960A1 (en) Markers Related to Age-Related Macular Degeneration and Uses Therefor
US20140342919A1 (en) Markers related to age-related macular degeneration and uses therefor
US20220177982A1 (en) Methods Of Identifying Subjects Having An Increased Risk Of Developing A Coronavirus Infection And Treatment Thereof
Zhu et al. MAPKAP1 rs10118570 polymorphism is associated with anti-infection and anti-hepatic fibrogenesis in schistosomiasis japonica
US9670545B2 (en) Methods and kits for treating and classifying individuals at risk of or suffering from TRAP1 change-of-function
Halu et al. Integrative multi-omic analyses identify major axes of heterogeneity in chronic obstructive pulmonary disease and uncover their molecular contributors
EP4058595A1 (en) Methods for using low-dose colchicine after myocardial infarction
Stanioniene et al. FBN1 polymorphisms in patients with the dilatative pathology of the ascending thoracic aorta
BR112015019502B1 (pt) Método in vitro e/ou ex vivo para determinar se um sujeito humano apresenta ou está em risco de desenvolver doença pulmonar intersticial
BR122023008116B1 (pt) Método in vitro e/ou ex vivo para avaliar a eficácia do tratamento contra a doença pulmonar intersticial em um sujeito humano
BR122023008110B1 (pt) Método in vitro e/ou ex vivo para determinar se um sujeito humano apresenta ou está em risco de desenvolver doença pulmonar intersticial

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201228

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210401

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220720